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doi:10.1016/j.ejvs.2009.05.027Abstract Objectives: When compared to compression therapy alone, surgical correction of
superficial venous reflux (SVR) reduces recurrence but does not appear to increase healing
of chronic venous ulceration (CVU). The role of ultrasound-guided foam sclerotherapy (UGFS)
of SVR as part of the treatment of CVU remains uncertain. The aim of this study is to describe
CVU healing and recurrence rates after UGFS and to relate these outcomes to patterns of pre-
and post-intervention venous reflux.
Methods: A prospective study of 27 consecutive patients (28 legs) of median age 69 (interquar-
tile range 54e79) years undergoing UGFS for SVR in addition to compression for treatment of
CVU of median duration 12 (IQR 6e23) months. Prior to and 1, 6, and 12 months after treat-
ment patients underwent clinical and duplex assessment.
Results: 8 limbs (29%) had deep and superficial venous reflux, and 20 limbs had SVR alone.
There was a history of DVT in 4 limbs, and 4 patients were on warfarin. No limbs had significant
arterial disease and all received post-UGFS compression. Median volume of (3% STD) foam used
was 8 (range 2e14) ml. 1, 3 and 6 months after UGFS, 22 (79%), 27 (96%) and 27 (96%) CVU had
healed. At 12 months, 25 ulcers remained healed, 2 ulcers had recurred; one patient had died
from carcinomatosis.
Discussion: Following UGFS as an adjunct to compression, 96% of CVU healed within 3 months
and only 2 healed ulcers (7%) had recurred at 12 months. UGFS appears to be an attractive
minimally-invasive alternative to surgery to treat SVR in patients with CVU, especially the
elderly and frail.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.arvall, Birmingham University, Department of Vascular Surgery, Flat 5 Netherwood House, Solihull
lands B91 2JL, UK. Tel./fax: þ44 0121 424 5086.
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Foam Sclerotherapy for Chronic Venous Ulceration 765Introduction less than 30 min. Immediately prior to treatment patientsApproximately 1% of Europeans will develop chronic venous
ulceration (CVU) during their life time; the point preva-
lence of open ulceration is estimated at 0.1%. CVU has
a significant adverse impact on health-related quality of
life (HRQL) and the condition consumes significant health
care resources.1e3 The treatment of CVU remains contro-
versial and outcomes are often disappointing, especially in
the presence of (post-thrombotic) deep venous reflux
(DVR). However, a recent randomised controlled trial
(ESCHAR) comparing compression alone with compression
plus superficial venous surgery in patients with superficial
venous reflux (SVR) and CVU found that, although there
appeared to be no difference in healing rates, recurrence
rates were significantly lower in the surgery group.4 Healing
rates were 65% at 6 months and approached 80% at 12
months; recurrence rates were 34% in the compression
alone group and 15% in the surgery and compression group
at a median follow-up of 14 months.4
Two groups have published data to suggest that ultra-
sound-guided foam sclerotherapy (UGFS) of SVR in patients
with CVU may be an effective and attractive alternative to
surgery in this often elderly and frail population.5,6
However, one study was retrospective, the other reported
only 6 week follow-up, and neither study included duplex
follow-up to assess residual or recurrent reflux and its
relationship with ulcer healing.
The aim of this study, therefore, was prospectively to
describe the rate of CVU healing and recurrence during the
12 months following UGFS of SVR, and also to assess the
relationship between healing, recurrence and the pattern
and severity of post-intervention venous reflux as deter-
mined by serial duplex ultrasound.Methods
Local ethics committee approval and written informed
consent were obtained. Consecutive patients undergoing
UGFS in addition to compression as part of their treatment
for open (CEAP clinical grade 6)7 CVU were enrolled between
June 2005 and June 2007. All patients were NHS patients
referred to the Heart of England NHS Foundation Trust by
their general practitioners. All patients were assessed in
a Consultant-led NHS outpatient clinic (AB, DA) where an
ulcer history was taken, ankle-brachial pressure index (ABPI)
was measured and a venous duplex scan was performed (AB,
GB) to determine sites of venous reflux. Patients without
SVR, those with an ABPI <0.8, those refusing to undergo
UGFS, and those in whom the ulcer had healed prior to UGFS
treatment were excluded. Patients were put on the waiting
list for UGFS (approximately 4e6 weeks) and the ulcerated
limb was placed into multilayer compression bandaging,
Profore or Proguide (Smith and Nephew, Hull, UK) delivering
40 mmHg at the ankle while awaiting treatment.
UGFS treatment
UGFS was performed by one of the authors (AB, DA) on an
outpatient basis in a treatment room. All treatments tookunderwent repeat venous duplex scanning (GB) and
the incompetent saphenous trunks and superficial varices
were marked on the skin. The patient then reclined in the
supine (GSV) or prone (SSV) position and the saphenous
trunk was cannulated with a peripheral intravenous cath-
eter (Optiva, Medex Medical Ltd, Rossendale, UK) under
direct ultrasound guidance. 18e22 g cannulae (green, pink
or blue) were used according to the size and depth of the
target vein. 1e4 cannulae were inserted according to the
extent of reflux. Once all cannulae were secured the limb
was held in an elevated position for injection of the foam.
Prior to injection all cannulae were flushed with normal
saline to ensure no movement had occurred during the
changes in limb position. Sclerosant foam was prepared by
modified Tessari’s method using two, 2 ml syringes (Tessari
described using one 2 ml and one 5 ml syringe) connected
by a 3-way tap and a 5-micron filter (B Braun Medical,
Sheffield, UK) and comprised 0.5 ml 3% sodium tetradecyl
sulphate (Fibrovein, STD Pharmaceuticals Ltd, Hereford,
UK) and 2 ml air. Foam was injected in 2 ml aliquots (to
a maximum of 14 ml) and its distribution and resultant
venous spasm observed by duplex imaging. At least 30 s
were allowed to pass between injecting each aliquot of
foam. After each injection patients were asked to dorsi-
and plantar-flex their ankle several times to clear any foam
that might have entered the deep venous system. When all
the trunk and tributary veins and the varices were in spasm
and fully occluded with foam the cannulae were removed
and compression was applied with the limb still held in the
elevated position. A roll of Velband (Johnson and Johnson
Medical, Ascot, Berkshire, UK) was applied directly along
the line of the previously marked saphenous trunk and
superficial varices, and retained on the thigh using Peha-
haft cohesive bandage (Hartmann, Germany). Below-knee
multilayer compression bandaging was applied as previ-
ously, and a thigh-length class II compression stocking (with
the foot/lower leg portion removed) was applied over the
top (Medi, Hereford, UK e produces 23e32 mmHg at the
ankle). The thigh bandaging was left in place for 7e10 days
when the patient was reviewed in clinic, at which time the
bandaging was removed and the class II stocking worn
(along with the below-knee multilayer compression
bandaging) for a further 3 weeks. Compression bandaging
was changed as necessary according to the amount of
exudate.Pre-treatment duplex and clinical assessment
All duplex examinations were performed in a standard
manner by one of the authors (GB). Patients were examined
standing with their weight on the contralateral limb and the
leg to be examined slightly bent with the heel on the floor
to relax the calf muscle while maintaining stability, with
a Sonosite Micromaxx (Sonosite Ltd, Hitchin, Herts, UK)
fitted with a 10 MHz transducer. The following venous
segments were insonated: proximal and distal superficial
femoral vein; above and below-knee popliteal vein;
saphenofemoral and saphenopopliteal junctions, the whole
length of the GSV and the SSV. All veins were assessed for
patency and compressibility. Reflux was induced with
766 K.A.L. Darvall et al.a manual calf squeeze and was defined as reverse flow of
greater than 0.5 s. Incompetent perforating veins were not
specifically sought.
Outcome measures and follow-up
The chosen outcome measures were ulcer healing and
complete occlusion of, and abolition of reflux in, the
treated saphenous trunks on venous duplex. All patients
were seen at 7e10 days and 1, 6 and 12 months after
treatment in a dedicated research clinic by the Vascular
Specialist Nurse (GB) and a Venous Research Fellow (KD,
surgical trainee) where their legs were examined and
a duplex scan was repeated. At the first visit the bandages
were removed and a duplex was performed to look specif-
ically for DVT; patients were also asked whether they had
had any complications following their treatment. Patients
were specifically asked about visual disturbance, head-
ache, and skin and possible nerve problems in the treated
leg.
Ulcer healing was defined as complete re-epithelialisa-
tion of the leg, and ulcer recurrence as any loss of skin
continuity below the knee. All treated limbs underwent
repeat venous duplex examination at each follow-up visit as
per the pre-treatment duplex. In addition, occlusion of the
treated saphenous trunk was determined by a lack of
compressibility and the absence of any flow. Complete
occlusion was defined as occlusion in the entire length of
the treated GSV or SSV. Recanalisation was defined as the
presence of flow in either an antegrade or retrograde
direction in a previously occluded segment. Patients with
residual or recurrent saphenous truncal reflux were offered
further treatment by repeating foam sclerotherapy with 3%
STD (Fibrovein) as outlined above. After ulcer healing was
achieved patients wore below-knee class II stockings (Medi,
Hereford, UK) and patients were advised to wear these
during the day.
Results
Twenty-seven patients (28 limbs) of median age 69 (inter-
quartile range [IQR] 54e79) years with open CVU of primary
aetiology (CEAP C6, EP) were treated between June 2005
and June 2007. Demographic data, ulcer history, and pre-
UGFS duplex findings are shown in Table 1. ABPI was normal
(>0.9) in all limbs. SVR alone (AS) was present in 20 limbs
and 8 limbs had mixed SVR and DVR (ASD); all limbs had
reflux (PR) rather than obstruction. 4 patients had
a previous history of DVT; this was multiple in two patients
and they consequently were on lifelong warfarin, one with
a target INR of 4.5, the other 3.5. Two other patients were
on warfarin for atrial fibrillation with target INR of 2e3.
Median ulcer duration (IQR) was 12 (6e23) months. There
were no symptomatic DVTs in any of the treated limbs,
neither was there evidence of DVT on duplex at 7e10 days
or 1, 6 or 12 month follow-up. There were no episodes of
visual disturbance or other neurological symptoms, no
cutaneous ulceration at cannulation sites, or paraesthesia.
At 1 and 6 months after treatment with a median
(range) of 8 ml (2e14 ml) foam 22 ulcers (79%) and 27 ulcers
(96%) respectively had healed completely (Table 2, Fig. 1).Although the patients were not seen personally by the
investigators at hospital between 1 and 6 months, all were
reported by community carers to have healed their ulcers
within 3 months of treatment. One patient whose ulcer
had not healed at 1 month died soon after from carcino-
matosis and was, therefore, excluded from further anal-
ysis. At 12 months, 25 ulcers (93%) remained healed and
two ulcers had recurred (7%). Both patients who had
recurrence at 12 months had stopped wearing their
compression stockings, and both also had DVR prior to
(and after) treatment.
Total occlusion of all treated veins at 1 month was
observed in 22 of 28 limbs (Table 2, Fig. 1). Two patients
had had unsuccessful treatment: one refused further
treatment (patient 19) and the other had repeat UGFS
although the ulcer was already healed (patient 18). Three
patients had residual below-knee GSV reflux only with an
occluded GSV in the thigh (patients 2, 9 and 20). All of these
patients’ ulcers had healed by 1 month and only one wan-
ted further treatment (patient 9) for residual visible vari-
cose veins (VV). The remaining one patient (patient 11) only
had occlusion of her proximal GSV after the first treatment
with many remaining VV and distal reflux. Her previously
almost circumferential ulcer however was much improved
and she did not want further injections.
At 6 month follow-up 22 of 27 limbs (patient 19 lost to
follow-up) had total occlusion of all treated veins. Patients
2 and 20 still had residual below-knee GSV reflux and
patient 11 still only had occlusion of the proximal GSV. The
remaining two patients had had recanalisation of their
below-knee GSV with recurrent reflux (patients 23 and 26).
In both patients the ulcers remain healed and they only had
a few VV so no further treatment was wanted.
At 12 months, 19 of 27 limbs had total occlusion of all
treated veins. The situation for patients 2 and 20 (residual
below-knee GSV reflux) and patients 23 and 26 (recurrent
below-knee reflux) remained unchanged. Patients 3, 4 and
15 had recanalisation of the majority of their GSV with
recurrent reflux at 12 months follow-up. However, their
ulcers remained healed and they had few visible VV and
remained asymptomatic, so they elected to have no further
treatment at this stage. Finally, patient 11 had a recur-
rence of her ulcer between 6 and 12 months and continued
to have distal reflux and many VV amenable to treatment
with UGFS. However, the ulcers are intermittent and her
symptoms are much improved so she continues to decline
further treatment.Discussion
The main findings of the present study are that following
UGFS combined with compression, 27 of 28 (96%) CVU
healed within 3 months, and at 12 months only 2 ulcers had
recurred.
The outcomes reported here after UGFS plus compres-
sion appear to be superior to those reported from other
studies where only compression has been used and no
attempt has been made to eradicate SVR (healing 68e83%
at 6 months, recurrence 26e28% at 12 months).8e10
The importance of eradicating SVR was clearly demon-
strated in the ESCHAR study which was a randomised
Table 1 Pre-treatment data.
Demographics Ulcer characteristics Refluxing segments on duplexa
Patient Gender Age Site Duration Compressionb DV GSV SSV
1 F 87 Lateral 10y þ þ e þ
2 M 86 Medial 12m þ þ þ e
3 F 67 Medial 6m   þ 
4 M 22 Medial 2y   þ 
5 M 58 Medial 9m   þ 
6 F 53 Medial 9m þ  þ 
7 F 74 Lateral 4m þ  þ 
8 F 56 Medial 9y þ  þ 
9 M 79 Medial 4y   þ 
10 F 70 Medial 6m  þ  þ
11 F 56 Medial 4y þ þ þ 
12 F 89 Medial 3m   þ 
13 M 68 Medial 12m þ þ þ 
14 M 62 Medial 12m   þ 
15 F 55 Lateral 2y þ  þ 
16 F 80 Lateral 12m þ  þ 
17 M 52 Medial 6m   þ 
18 F 38 Medial 7m   þ 
19 M 86 Medial 40y þ  þ 
20 M 49 Lateral 12m   þ 
21 M 79 Medial 20m   þ 
22 F 75 Lateral 4m  þ þ 
23 F 81 Medial 8m   þ 
24 M 51 Medial 12m þ  þ 
25 M 70 Medial 12m þ þ þ 
26 F 79 Medial 3m  þ þ þ
27-R F 54 Lateral 12m   þ 
27-L F 54 Lateral 12m   þ 
a þZ Reflux present; Z no reflux. DVZ deep veins (superficial femoral and or popliteal vein); GSVZ great saphenous vein;
SSVZ small saphenous vein.
b þZ Compression bandaging used to treat current ulcer; Z no compression tried.
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recurrence rates after treatment with compression
bandaging alone, and compression combined with superfi-
cial venous surgery.4 Healing rates at 6 months were 65% in
both groups, and approached 80% by 12 months.4 Recur-
rence rates, however, were significantly lower in patients
undergoing surgery, 15% vs. 34% at a median follow-up of 14
months (range 10e23 months).4 Longer term follow-up from
the same study found ulcer healing rates at three years of
89% in the compression group and 93% in the compression
and surgery group (PZ 0.73, log rank test); and ulcer
recurrence rates at 4 years of 56% in the compression group
and 31% for the compression and surgery group (P< 0.01).11
The CVU outcomes reported here after UGFS appear to
be at least as good as those reported after surgery in the
ESCHAR study (nZ 216), although the numbers in the
studies are very different. This suggests that UGFS may be
an attractive alternative to surgery in this group of patients
who are often elderly, frail and refuse (or are refused)
operative intervention; further supporting this is the lack of
side-effects found in this clinical series and the successful
treatment of 4 patients anticoagulated with warfarin. Twoother groups have thus far looked at the effect of UGFS on
CVU healing and have also reported promising results.
In 2004, Cabrera et al. reported a retrospective study of
116 consecutive patients with 151 ulcers of median dura-
tion (range) 62 (1e480) months treated over a 10-year
period with 0.27% to 1% polidocanol CO2 microfoam. Almost
30% of their patients had deep venous reflux and 20 had
undergone previous surgery (unspecified). Unlike the
present study where only 2 of the 28 treated limbs required
two sessions of UGFS, their patients underwent repeated
treatment sessions (median 3.6, range 1e17) until all
identifiable SVR was eliminated. At 6 months, Cabrera
reported an 86% healing rate (96/116) with a median time
to healing of 2.7 months (8 weeks); 7 patients were never
healed, one patient was lost to follow-up and there were
recurrences in 10 patients. These outcomes are very similar
to those reported here. In a multivariate analysis they
found that both long ulcer duration and the presence of
DVR were adverse prognostic factors; the latter appears to
be the case in the present series too. Beyond 6 months,
follow-up rates in the Spanish study were really too low to
undertake proper analysis of longer term healing and
Table 2 Treatment and follow-up data.
Treatment data Ulcers completely
healed at follow-upa
All treated venous segments
occluded on follow-up duplex
scanb
Patient No. of cannulae Volume of foam (ml) 1m 6m 12m 1m 6m 12m
1 1 2 þ þ þ þ þ þ
2 1 12 þ þ þ   
3 1 8 þ þ þ þ þ 
4 2 12 þ þ þ þ þ 
5 1 8 þ þ þ þ þ þ
6 2 10 þ þ þ þ þ þ
7 3 8  þ þ þ þ þ
8 2 12  þ þ þ þ þ
9 2 8 þ þ þ  þ þ
10 2 8 þ þ þ þ þ þ
11 2 8  þ    
12 1 8 þ þ þ þ þ þ
13 2 10 þ þ þ þ þ þ
14 2 10 þ þ þ þ þ þ
15 1 8 þ þ þ þ þ 
16 2 8 þ þ þ þ þ þ
17 1 8  þ þ þ þ þ
18 2 10 þ þ þ  þ þ
19 1 4  
20 1 8 þ þ þ   
21 2 12  þ þ þ þ þ
22 1 3 þ þ  þ þ þ
23 1 8 þ þ þ þ  
24 3 10 þ þ þ þ þ þ
25 2 8 þ þ þ þ þ þ
26 4 14 þ þ þ þ  
27-R 2 10 þ þ þ þ þ þ
27-L 1 6 þ þ þ þ þ þ
a þZ Completely healed; Z not healed; left blankZ lost to follow-up (died).
b þZ All treated venous segments occluded and no residual reflux; Z some reflux present; left blankZ lost to follow-up (died).
Figure 1 Ulcer healing rates and treated vein occlusion rates
after ultrasound-guided foam sclerotherapy.
768 K.A.L. Darvall et al.recurrence rates; and repeated post-intervention duplex
scans to assess the success of their treatment were not
undertaken. However, the authors reasonably concluded on
the basis of their short term results that microfoam treat-
ment of ulcers was promising and worthy of further
study.5,12
In 2006, Bergan et al. reported their experience of 50
limbs with active CVU. 22 were treated with compression
bandaging alone, 13 failed compression therapy and went
on to have UGFS, and a further 15 were treated promptly
with UGFS.6 Polidocanol foam was used in strengths of
1e3%, and the usual volume used was 8 ml. At 6 weeks
follow-up they found complete ulcer healing in 45% of the
compression only group, and 100% of the patients who had
had UGFS.6 The same authors suggest that this observed
increased efficacy of UGFS over superficial venous surgery
in CVU healing could be due to the fact that the foamed
sclerosant can act directly on the microcirculation (the end
point of venous hypertension), rather than indirectly by
superficial venous stripping.13
Also, GSV stripping is usually carried out to knee level
only due to the risk of damage to the saphenous nerve
Foam Sclerotherapy for Chronic Venous Ulceration 769below the knee,14 with nearly one-third of patients having
reflux in the distal GSV at follow-up in one study.15 Kulkarni
et al., however, concluded that residual reflux after
saphenous surgery is not the most important predictor of
venous ulcer recurrence, although the hazard ratio of
developing ulcer recurrence by 3 years was 2.5 in those
with residual below-knee GSV reflux, this did not reach
statistical significance.16 Neither the Spanish nor the US
groups considered the effect of technically ‘‘successful’’
treatment (i.e. occlusion of all treated veins on duplex) on
ulcer healing and recurrence. In the current study, of the 3
patients who still had residual reflux in the thigh GSV at 1
month, only one ulcer had healed. 5 limbs have had some
recurrence of reflux by 12 months but in none of these limbs
have the ulcers recurred. It will be interesting to see
whether these patients go on to develop recurrent ulcera-
tion and hence whether it would be useful to treat these
asymptomatic ‘‘recurrences’’ to prevent this. Of the 2
patients with recurrent ulceration, both have deep venous
reflux and one continued to have significant superficial
reflux also.
The small number of patients is an inherent weakness in
the study, but as a preliminary study it demonstrates the
potential of UGFS as an adjunct to healing CVU. The results
must be interpreted with caution due to the fact that only
12 of 28 limbs had been treated by compression prior to
assessment for treatment. This is slightly offset by the
observation that none of the ulcers healed in the interval
between placement on the waiting list for treatment and
attending for UGFS (usually 4e6 weeks), during which time
all limbs were treated with multilayer graduated
compression bandaging. Another obvious limitation is that
this study is not a randomised controlled trial. Although the
authors (DA, AB) offer all patients a choice between surgery
and UGFS as appropriate, in our practice patients rarely
choose a surgical option. The striking differences we have
observed between the outcomes following UGFS and
surgery have removed our ‘grey area of clinical equipoise’
and we therefore feel it inappropriate for us to randomise
patients between the two treatments. Even if we did wish
to do that type of study, it is clear that the great majority
of our patients would simply refuse randomisation. In these
particular patients, this problem of recruitment and suit-
ability for treatment has been demonstrated in the pub-
lished RCTs.17
In summary, our preliminary data add further weight to
the suggestion that eradication of SVR by means of UGFS
improves CVU outcomes when compared to compression
alone. In this regard, UGFS appears to be at least as
effective as surgery as a means of dealing with SVR and
does, therefore, appear the more attractive option in this
elderly patient population. As is probably to be expected,
patients with DVR do not respond as well to treatment with
UGFS but this is also true of surgery and compression
alone. Furthermore, the novel follow-up duplex data pre-
sented here does suggest long-term healing following UGFS
probably requires careful follow-up and, if required,
further sessions of UGFS to make sure that SVR remains
completely eradicated. Encouraged by these promising
early results the authors have embarked upon a larger
study to look at the role of UGFS in the treatment of CVU
in greater depth.Conflict of Interest/Funding
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